Century Therapeutics, Inc. Depreciation
Century Therapeutics, Inc. (IPSC) reported Depreciation of $26.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-12
- Century Therapeutics, Inc. depreciation for the quarter ending 2026-06-30 was $26.00K, a 99.19% decline year-over-year.
- Century Therapeutics, Inc. depreciation for the quarter ending 2026-03-31 was $3.00M, a 6.74% decline year-over-year.
- Century Therapeutics, Inc. depreciation for the quarter ending 2025-12-31 was $3.55M, a 6.99% increase year-over-year.
- Century Therapeutics, Inc. depreciation for the quarter ending 2025-09-30 was $3.13M, a 5.10% decline year-over-year.
- Century Therapeutics, Inc. depreciation for fiscal 2025 was $13.10M, a 1.53% decline from fiscal 2024.
- Century Therapeutics, Inc. depreciation for fiscal 2024 was $13.30M, a 1.99% increase from fiscal 2023.
- Century Therapeutics, Inc. depreciation for fiscal 2023 was $13.04M, a 54.55% increase from fiscal 2022.
- Century Therapeutics, Inc. depreciation for fiscal 2022 was $8.44M, a 125.19% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $26.00K 10-Q · filed 2026-08-12 | $5.62M 10-Q · filed 2026-08-12 | $6.58M derived: sum of 3 quarters · filed 2026-08-12 | $9.71M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $3.00M 10-Q · filed 2026-05-13 | $6.55M derived: sum of 2 quarters · filed 2026-05-13 | $9.68M derived: sum of 3 quarters · filed 2026-05-13 | $12.88M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $3.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $6.68M derived: sum of 2 quarters · filed 2026-03-12 | $9.88M derived: sum of 3 quarters · filed 2026-08-12 | $13.10M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $3.13M 10-Q · filed 2025-11-13 | $6.33M derived: sum of 2 quarters · filed 2026-08-12 | $9.55M 10-Q · filed 2025-11-13 | $12.87M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $3.20M 10-Q · filed 2026-08-12 | $6.42M 10-Q · filed 2026-08-12 | $9.74M derived: sum of 3 quarters · filed 2026-08-12 | $13.04M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $3.22M 10-Q · filed 2026-05-13 | $6.54M derived: sum of 2 quarters · filed 2026-05-13 | $9.84M derived: sum of 3 quarters · filed 2026-05-13 | $13.30M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $3.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $6.62M derived: sum of 2 quarters · filed 2026-03-12 | $10.08M derived: sum of 3 quarters · filed 2026-03-12 | $13.30M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $3.30M 10-Q · filed 2025-11-13 | $3.00K 10-Q · filed 2024-11-05 | $6.76M derived: sum of 2 quarters · filed 2025-11-13 | $9.99M 10-Q · filed 2025-11-13 | $13.54M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $3.46M 10-Q · filed 2025-08-14 | $6.69M 10-Q · filed 2025-08-14 | $10.24M derived: sum of 3 quarters · filed 2025-08-14 | $13.59M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $3.23M 10-Q · filed 2025-05-15 | $6.78M derived: sum of 2 quarters · filed 2025-05-15 | $10.13M derived: sum of 3 quarters · filed 2025-05-15 | $13.36M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $3.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $6.90M derived: sum of 2 quarters · filed 2025-03-19 | $10.14M derived: sum of 3 quarters · filed 2025-03-19 | $13.04M 10-K · filed 2025-03-19 | |
| 2023-09-30 | $3.35M 10-Q · filed 2024-11-05 | $6.58M derived: sum of 2 quarters · filed 2024-11-05 | $9.49M 10-Q · filed 2024-11-05 | $12.33M derived: sum of 4 quarters · filed 2024-11-05 | |
| 2023-06-30 | $3.23M 10-Q · filed 2024-08-08 | $6.14M 10-Q · filed 2024-08-08 | $8.98M derived: sum of 3 quarters · filed 2024-08-08 | $11.75M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $2.91M 10-Q · filed 2024-05-09 | $5.75M derived: sum of 2 quarters · filed 2024-05-09 | $8.52M derived: sum of 3 quarters · filed 2024-05-09 | $10.19M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $5.61M derived: sum of 2 quarters · filed 2024-03-14 | $7.28M derived: sum of 3 quarters · filed 2024-03-14 | $8.44M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $2.77M 10-Q · filed 2023-11-09 | $4.44M derived: sum of 2 quarters · filed 2023-11-09 | $5.60M 10-Q · filed 2023-11-09 | $6.65M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $1.67M 10-Q · filed 2023-08-09 | $2.83M 10-Q · filed 2023-08-09 | $3.88M derived: sum of 3 quarters · filed 2023-08-09 | $4.92M derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | $1.16M 10-Q · filed 2023-05-11 | $2.21M derived: sum of 2 quarters · filed 2023-05-11 | $3.25M derived: sum of 3 quarters · filed 2023-05-11 | $4.19M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $2.10M derived: sum of 2 quarters · filed 2023-03-16 | $3.03M derived: sum of 3 quarters · filed 2023-03-16 | $3.75M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $1.04M 10-Q · filed 2022-11-10 | $1.98M derived: sum of 2 quarters · filed 2022-11-10 | $2.70M 10-Q · filed 2022-11-10 | $3.21M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $935.00K 10-Q · filed 2022-08-11 | $1.65M 10-Q · filed 2022-08-11 | $2.16M derived: sum of 3 quarters · filed 2022-08-11 | $2.57M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $718.00K 10-Q · filed 2022-05-16 | $1.23M derived: sum of 2 quarters · filed 2022-05-16 | $1.64M derived: sum of 3 quarters · filed 2022-05-16 | $1.92M derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | $510.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $920.00K derived: sum of 2 quarters · filed 2022-03-17 | $1.20M derived: sum of 3 quarters · filed 2022-03-17 | $1.40M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $410.00K 10-Q · filed 2021-11-10 | $692.00K derived: sum of 2 quarters · filed 2021-11-10 | $892.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $282.00K 10-Q · filed 2021-08-12 | $482.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |